IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19

IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19

Serum Institute of India CEO Adar Poonawalla. File Photo

New Delhi, October 22

Non-profit scientific research organisation IAVI, vaccine major Serum Institute of India and global science and technology firm Merck KGaA have entered into an agreement to develop monoclonal antibodies to fight COVID-19 and to ensure their prompt and equitable global access.

The agreement is "to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic", the partners said in a statement on Thursday.

The agreement builds on the advanced antibody discovery and optimisation expertise of International AIDS Vaccine Initiative (IAVI) and Scripps Research, and on Germany's Merck KGaA's and Serum Institute's significant capabilities in design and scale up of accelerated manufacturing processes for mAb production, it added.

If the SARS-CoV-2 neutralising antibody candidates being advanced through this partnership are shown to be efficacious in clinical trials, either as a single antibody or a potential combination of both candidates, Merck KGaA will lead commercialisation in developed countries, read the statement.

Serum Institute will lead global manufacturing as well as commercialisation in low and middle-low-income countries, including India, it added.

"We're acutely aware of the tremendous potential for monoclonal antibodies to be used in COVID-19 response. By combining the scientific achievements of IAVI and Scripps Research with our partners' development, manufacturing, and distribution expertise, we are hopeful that this partnership will result in globally accessible antibodies that are available to all who can benefit from them," said IAVI president and CEO Mark Feinberg.     On the agreement, Merck KGaA vice chair of the executive board and deputy CEO  Belén Garijo said: "Together with IAVI and Serum Institute, we look forward to demonstrating the potential application of these monoclonal antibodies in the management of COVID-19."        

We share a common purpose to accelerate this promising science and deliver effective solutions that address global challenges presented by this pandemic, he added.

"I am extremely pleased that we have joined forces with IAVI and Merck KGaA, Darmstadt, Germany in the fight against COVID-19 with the aim of developing monoclonal antibodies for global access," said Serum Institute of India CEO Adar Poonawalla.

Under IAVI's agreement with Merck KGaA and Serum Institute, the partners will conduct an accelerated, integrated programme of preclinical and clinical research to evaluate the antibodies for treatment of COVID-19. A Phase I clinical trial is expected to start early in 2021, read the statement.

Should the mAb candidates being developed prove safe and efficacious, Merck KGaA and Serum Institute will help ensure that the therapy is rapidly and widely available and accessible, it added.    

Joining the partners in this development effort are contract research and manufacturing firm Syngene International and bioengineering company ATUM, the statement added. PTI

 

Don't Miss

Arrival of pets has been the exact disruption we needed

Arrival of pets has been the exact disruption we needed

Modi to Ganguly, how different is BCCI?

Modi to Ganguly, how different is BCCI?

Sins of the father & the aftermath

Sins of the father & the aftermath

Summer of 69, in Himalayas

Summer of 69, in Himalayas

Congress in need of overhaul

Congress in need of overhaul

Top Stories

Night curfew to be imposed in Punjab as Capt announces fresh curbs from December 1

Night curfew to be imposed in Punjab as Capt announces fresh curbs from December 1

Fine for not wearing masks to be doubled from Rs 500 to Rs 1...

Argentina's Maradona, one of soccer's greatest, dies aged 60

Argentina's Maradona, one of soccer's greatest, dies aged 60

Legend suffered a heart attack at his home in the outskirts ...

Home Ministry issues new COVID guidelines for December

Home Ministry issues new COVID guidelines for December

States/UTs mandated to strictly adhere to containment measur...

'Delhi Chalo' protest: Haryana Police use water cannon on farmers in Karnal

'Delhi Chalo' protest: Haryana Police use water cannon on farmers in Karnal

Haryana deploys police in large numbers, imposes Section 144...

Cities

View All